A Phase 2 interventional study of Alisertib in Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-11.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leukemia, Myeloid, Acute by Takeda — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Takeda.
Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2009, is one of 3 in phase 2, and was the 6th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 14 studies in Leukemia, Myeloid, Acute by Takeda is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 5 · Phase 3 2
First in 1997; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 60 across the 13 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). This study looked at the antitumor activity in people who received alisertib.
The study enrolled 57 patients. Participants were categorized by disease sub-types AML and MDS. Participants received:
All participants took alisertib capsules every 12 hours each day for 7 days followed by a 14-day rest period in 21-day cycles for approximately 26 cycles.
This multi-center trial was conducted in North America and France. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. The participant could continue treatment beyond 12 months if it was considered by the Sponsor and the Investigator that they would derive benefit from continued alisertib treatment. Participants had weekly blood work and clinic visits, with disease assessments every 2 cycles (ie. every 6 weeks) up to and including Cycle 16. Reduced visits (every 12 weeks) were conducted for participants tolerating treatment beyond Cycle 16 and for participants off treatment without disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participants must meet all of the following inclusion criteria:
Eligible diagnoses:
Female participants:
Male participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
Drug: Alisertib
Alisertib capsules
Also known as: MLN8237
Best Overall Response Rate (ORR) Based on Investigator's Assessment
Best ORR is defined as the number of participants with complete remission(CR) or partial remission(PR) assessed by the Investigator using modified AML/MDS International Working Group(IWG) Criteria. AML:CR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, bone marrow blasts(BMB) \<5%, transfusion independent, no extramedullary disease(EMD); CRi=BMB \<5%, transfusion independent, no EMD; PR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, BMB \>50% decrease and 5% to 25%, blasts \<5% with Auer rods; PRi=BMB \>50% decrease and 5% to 25%. MDS:CR=bone marrow: ≤5% myeloblasts with normal maturation, peripheral blood: hemoglobin ≥11 g/dL, platelets ≥100x10\^9/L, neutrophils ≥1.0x10\^9/L, blasts 0%; PR=all CR criteria if abnormal before treatment except: BMB decreased by ≥50% over pretreatment but still \>5%; PRi=BMB decreased by ≥50% over pretreatment but still \>5%; Marrow CR=bone marrow: ≤5% myeloblasts and decrease by ≥50% over pretreatment, peripheral blood hematologic improvement responses noted.
Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Progression Free Survival (PFS)
PFS is defined as the time from the date of first study drug administration to the date of first documented progressive disease (PD) or death.
Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Duration of Response (DOR)
Duration of response is defined as the time from the date of first documentation of a response to the date of first documented PD.
Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Best Overall Hematologic Improvement (HI) Response for Myelodysplastic Syndrome Based on Investigator Assessment
Best overall HI response is defined as percentage of participants with response as assessed by Investigator based on IWG criteria: 1)Erythroid response (pretreatment,\<11 g/dL): hemoglobin (Hgb) increase by ≥1.5 g/dL, relevant reduction of units of red blood cell (RBC) transfusions by absolute number of at least 4 RBC transfusions/8 weeks compared to pretreatment transfusion number in previous 8 weeks. Only RBC transfusions given for Hgb of ≤9.0 g/dL pretreatment will count in RBC transfusion response evaluation. 2)Platelet response (pretreatment,\<100x10\^9/L):Absolute increase of ≥30x10\^9/L for participants starting-\>20x10\^9/L platelets, increase \<20x10\^9/L to \>20x10\^9/L by at least 100%. 3)Neutrophil response (pretreatment,\<1.0x10\^9/L):At least 100% increase and an absolute increase \>0.5x10\^9/L. 4)Progression or relapse after HI:At least 1 of following: 50% decrement from maximum response levels in granulocytes or platelets, or reduction in Hgb by ≥1.5 g/dL, or transfusion dependence.
Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug was determined by the Investigator.
Time frame: First dose of study drug to 30 days after last dose (Up to 18.9 months)
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events
Vital signs measurements (blood pressure, heart rate, and oral temperature) were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose of study drug to 30 days after last dose (Up to 18.9 months)
Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events
Abnormal Laboratory Values for Chemistry or Hematology tests that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose of study drug to 30 days after last dose (Up to 18.9 months)
Participants took part in the study at 19 investigative sites in France, Canada and the United States from 10 February 2009 to 04 July 2011.
| Milestone | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| Started | 46 | 11 |
| Completed | 0 | 0 |
| Not completed | 46 | 11 |
| Withdrew: Progressive disease | 18 | 8 |
| Withdrew: Symptomatic deterioration | 4 | 1 |
| Withdrew: Adverse event | 14 | 1 |
| Withdrew: Withdrawal by patient | 2 | 0 |
| Withdrew: Reason not specified | 8 | 1 |
Best ORR is defined as the number of participants with complete remission(CR) or partial remission(PR) assessed by the Investigator using modified AML/MDS International Working Group(IWG) Criteria. AML:CR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, bone marrow blasts(BMB) \<5%, transfusion independent, no extramedullary disease(EMD); CRi=BMB \<5%, transfusion independent, no EMD; PR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, BMB \>50% decrease and 5% to 25%, blasts \<5% with Auer rods; PRi=BMB \>50% decrease and 5% to 25%. MDS:CR=bone marrow: ≤5% myeloblasts with normal maturation, peripheral blood: hemoglobin ≥11 g/dL, platelets ≥100x10\^9/L, neutrophils ≥1.0x10\^9/L, blasts 0%; PR=all CR criteria if abnormal before treatment except: BMB decreased by ≥50% over pretreatment but still \>5%; PRi=BMB decreased by ≥50% over pretreatment but still \>5%; Marrow CR=bone marrow: ≤5% myeloblasts and decrease by ≥50% over pretreatment, peripheral blood hematologic improvement responses noted.
| participants | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| CR + PR | 6 | 0 |
| Complete Remission (CR + CRi + Marrow CRi) | 1 | 0 |
| Partial Remission (PR + PRi) | 5 | 0 |
| Stable Disease as Best Response | 17 | 2 |
PFS is defined as the time from the date of first study drug administration to the date of first documented progressive disease (PD) or death.
| days | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| Progression Free Survival (PFS) | 55.0 (47.0 to 67.0) | 38.0 (35.0 to 113.0) |
Duration of response is defined as the time from the date of first documentation of a response to the date of first documented PD.
| days | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| Duration of Response (DOR) | 409.0 (57.0 to 596.0) | — |
Best overall HI response is defined as percentage of participants with response as assessed by Investigator based on IWG criteria: 1)Erythroid response (pretreatment,\<11 g/dL): hemoglobin (Hgb) increase by ≥1.5 g/dL, relevant reduction of units of red blood cell (RBC) transfusions by absolute number of at least 4 RBC transfusions/8 weeks compared to pretreatment transfusion number in previous 8 weeks. Only RBC transfusions given for Hgb of ≤9.0 g/dL pretreatment will count in RBC transfusion response evaluation. 2)Platelet response (pretreatment,\<100x10\^9/L):Absolute increase of ≥30x10\^9/L for participants starting-\>20x10\^9/L platelets, increase \<20x10\^9/L to \>20x10\^9/L by at least 100%. 3)Neutrophil response (pretreatment,\<1.0x10\^9/L):At least 100% increase and an absolute increase \>0.5x10\^9/L. 4)Progression or relapse after HI:At least 1 of following: 50% decrement from maximum response levels in granulocytes or platelets, or reduction in Hgb by ≥1.5 g/dL, or transfusion dependence.
| percentage of participants | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|
| Erythroid Response | 0 |
| Platelet Response | 0 |
| Neutrophil Response | 0 |
| Progression or Relapse | 0 |
| Not Available | 91 |
| Unable to Assess | 9 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug was determined by the Investigator.
| participants | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| AE | 46 | 11 |
| SAE | 36 | 8 |
| Deaths | 20 | 2 |
Vital signs measurements (blood pressure, heart rate, and oral temperature) were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| Dyspnoea | 12 | 2 |
| Pyrexia | 10 | 2 |
| Hypotension | 8 | 0 |
| Atrial fibrillation | 4 | 1 |
| Tachycardia | 3 | 0 |
| Dyspnoea exertional | 2 | 1 |
| Hypertension | 1 | 1 |
| Supraventricular tachycardia | 2 | 0 |
| Weight decreased | 2 | 0 |
| Tachypnoea | 1 | 0 |
| Hyperthermia | 1 | 0 |
| Hypothermia | 1 | 0 |
| Bradycardia | 0 | 1 |
| Ventricular tachycardia | 1 | 0 |
Abnormal Laboratory Values for Chemistry or Hematology tests that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| Febrile neutropenia | 17 | 4 |
| Anaemia | 14 | 3 |
| Thrombocytopenia | 9 | 2 |
| Neutropenia | 5 | 3 |
| Leukopenia | 3 | 2 |
| Hypoalbuminaemia | 4 | 0 |
| Leukocytosis | 3 | 0 |
| Hypokalaemia | 3 | 0 |
| Hyponatraemia | 3 | 0 |
| Neutrophil count decreased | 3 | 0 |
| Hypocalcaemia | 2 | 0 |
| Clostridium difficile colitis | 2 | 0 |
| Febrile bone marrow aplasia | 1 | 0 |
| Hypoxia | 1 | 0 |
| Hyperkalaemia | 1 | 0 |
| Hypernatraemia | 1 | 0 |
| Hyperglycaemia | 1 | 0 |
| Hypoglycaemia | 1 | 0 |
| Hypomagnesaemia | 0 | 1 |
| Hypophospataemia | 1 | 0 |
| Alanine aminotransferase increased | 0 | 1 |
| Blood bilirubin increased | 1 | 0 |
| Oxygen saturation decreased | 1 | 0 |
| Blood culture positive | 1 | 0 |
| Blood magnesium decreased | 1 | 0 |
| Blood creatinine increased | 1 | 0 |
| White blood cell count decreased | 1 | 0 |
| Gilbert's syndrome | 1 | 0 |
| Lymphoedema | 1 | 0 |
| Platelet count decreased | 1 | 0 |
Collected over First dose of study drug to 30 days after last dose (Up to 18.9 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib 50 mg (Acute Myeloid Leukemia) | — | 36/46 (78.3%) | 45/46 (97.8%) |
| Alisertib 50 mg (Myelodysplastic Syndrome) | — | 8/11 (72.7%) | 11/11 (100%) |
| Event | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 13/46 | 4/11 |
| SepsisInfections and infestations | 5/46 | 2/11 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/46 | 0/11 |
| Disease progressionGeneral disorders | 4/46 | 1/11 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/46 | 1/11 |
| StomatitisGastrointestinal disorders | 2/46 | 1/11 |
| BacteraemiaInfections and infestations | 1/46 | 1/11 |
| Bacterial infectionInfections and infestations | 1/46 | 1/11 |
| FatigueGeneral disorders | 1/46 | 1/11 |
| Multi-organ failureGeneral disorders | 0/46 | 1/11 |
| Event | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 21/46 | 2/11 |
| FatigueGeneral disorders | 15/46 | 5/11 |
| NauseaGastrointestinal disorders | 19/46 | 3/11 |
| StomatitisGastrointestinal disorders | 13/46 | 4/11 |
| AlopeciaSkin and subcutaneous tissue disorders | 7/46 | 4/11 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/46 | 3/11 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/46 | 3/11 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/46 | 3/11 |
| AnaemiaBlood and lymphatic system disorders | 10/46 | 3/11 |
| NeutropeniaBlood and lymphatic system disorders | 5/46 | 3/11 |
Safety population was defined as all participants who received any amount of alisertib.
| Age, Continuous(years) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| Mean | 71.9 ± 7.41 | 69.5 ± 12.50 | 71.4 ± 8.54 |
| Age, Customized(participants) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| <60 years | 4 | 2 | 6 |
| ≥60 years | 42 | 9 | 51 |
| Sex: Female, Male(Participants) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| Female | 22 | 3 | 25 |
| Male | 24 | 8 | 32 |
| Race/Ethnicity, Customized(participants) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 34 | 9 | 43 |
| Not Reported | 10 | 2 | 12 |
| Race/Ethnicity, Customized(participants) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| White | 36 | 10 | 46 |
| Black or African American | 3 | 0 | 3 |
| Asian | 1 | 0 | 1 |
| Not Reported | 6 | 1 | 7 |
| Region of Enrollment(participants) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| United States | 33 | 9 | 42 |
| France | 11 | 2 | 13 |
| Canada | 2 | 0 | 2 |
| Height(cm) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| Mean | 165.8 ± 8.35 | 171.4 ± 9.98 | 167.0 ± 8.93 |
| Weight(kg) | Alisertib 50 mg (Acute Myeloid Leukemia) | Alisertib 50 mg (Myelodysplastic Syndrome) | Total |
|---|---|---|---|
| Mean | 73.7 ± 13.80 | 80.4 ± 17.27 | 75.0 ± 14.62 |
3 further baseline measures are reported on the registry.
Ran from Feb 2009 to primary completion in Feb 2010, 11 months.
Results were first posted in May 2018, 8 years 3 months after primary completion. A results delay was requested in Jan 2012.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 11 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →